GlaxoSmithKline in a Rare-Disease Pact with Prosensa for RNA-modulation Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.